Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL HEALTH SCREENING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL HEALTH SCREENING MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL HEALTH SCREENING MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 INDUSTRY INSIGHTS
7 REGULATORY FRAMWORK
8 GLOBAL HEALTH SCREENING MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 CHOLESTEROL TESTS
8.2.1 TOTAL CHOLESTEROL TEST
8.2.2 LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL
8.2.3 HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL
8.2.4 TRIGLYCERIDES
8.3 BLOOD PRESSURE TEST
8.4 DIABETES TEST
8.4.1 A1C TEST
8.4.2 FASTING/RANDOM BLOOD SUGAR TEST
8.4.3 GLUCOSE TOLERANCE TEST
8.5 STD’S
8.5.1 HIV
8.5.2 CHLAMYDIA
8.5.3 GONORRHEA
8.5.4 HPV
8.5.5 HEPATITIS B AND C
8.5.6 SYPHILIS
8.5.7 CHLAMYDIA
8.5.8 OTHERS
8.6 CANCER SCREENING
8.6.1 PROSTATE CANCER
8.6.2 BREAST CANCER
8.6.3 CERVICAL CANCER
8.6.4 COLORECTAL CANCER
8.6.5 LUNG CANCER
8.6.6 OTHERS
8.7 GENERAL TEST
8.7.1 VISION AND HEARING TESTS
8.7.2 BONE DENSITY TEST
8.7.3 OTHERS
8.8 OTHERS
9 GLOBAL HEALTH SCREENING MARKET, BY PANEL TYPE
9.1 OVERVIEW
9.2 MULTI-TEST PANELS
9.3 SINGLE-TEST PANELS
9.3.1 TELOMERE TESTS
9.3.2 OXIDATIVE STRESS TESTS
9.3.3 INFLAMMATION TESTS
9.3.4 HEAVY METAL TESTS
10 GLOBAL HEALTH SCREENING MARKET, BY SAMPLE TYPE
10.1 OVERVIEW
10.2 BLOOD
10.3 URINE
10.4 SALIVA
10.5 SERUM
10.6 OTHERS
11 GLOBAL HEALTH SCREENING MARKET, BY TECHNOLOGY
11.1 OVERVIEW
11.2 TRF (TERMINAL RESTRICTION FRAGMENT)
11.3 STELA (SINGLE TELOMERE LENGTH ANALYSIS)
11.4 IMMUNOASSAYS
11.5 MEDICAL IMAGING
11.6 QPCR
11.6.1 QPCR (QUANTITATIVE POLYMERASE CHAIN REACTION)
11.6.2 MMQPCR (MONOCHROME MULTIPLEX QPCR)
11.6.3 ATLQPCR (ABSOLUTE TELOMERE LENGTH QPCR)
11.7 Q-FISH (QUANTITATIVE FLUORESCENCE IN SITU HYBRIDIZATION)
11.7.1 PRINS (PRIMED IN SITU SUBTYPE OF Q-FISH)
11.7.2 FLOW-FISH
11.7.3 HT Q-FISH (HIGH THROUGHPUT Q-FISH)
11.8 OTHERS
12 GLOBAL HEALTH SCREENING MARKET, BY CONDITION
12.1 OVERVIEW
12.2 NEUROLOGICAL CONDITIONS
12.2.1 ALZHEIMER’S DISEASE
12.2.2 CHRONIC STRESS
12.3 METABOLIC DISORDERS
12.3.1 DIABETES MELLITUS
12.3.2 OBESITY
12.4 CARDIOVASCULAR DISEASE
12.4.1 ATHEROSCLEROSIS
12.4.2 CORONARY HEART DISEASE
12.5 MUSCULOSKELETAL DISORDERS
12.5.1 OSTEOPOROSIS
12.5.2 RHEUMATOID ARTHRITIS
12.6 IMMUNOLOGY-RELATED CONDITIONS
12.7 HEPATITIS C COMPLICATIONS
12.8 CANCER
12.8.1 BREAST CANCER
12.8.2 PROSTATE CANCER
12.8.3 COLORECTAL CANCER
12.8.4 LUNG CANCER
12.8.5 CERVICAL CANCER
12.8.6 OTHERS
12.9 INFLAMMATORY CONDITIONS
12.9.1 ALLERGIES
12.9.2 ASTHMA
12.9.3 ARTHRITIS
12.9.4 AUTOIMMUNE CONDITIONS
12.9.5 INFLAMMATORY DIGESTIVE PROBLEMS
12.1 OTHERS
13 GLOBAL HEALTH SCREENING MARKET, BY SAMPLE COLLECTION SITES
13.1 OVERVIEW
13.2 HOME
13.3 OFFICES
13.4 HOSPITALS
13.4.1 PUBLIC
13.4.2 PRIVATE
13.5 DIAGNOSTIC LABORATORIES
13.6 OTHERS
14 GLOBAL HEALTH SCREENING MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDERS
14.3 RETAILS SALES
14.4 OTHERS
15 GLOBAL HEALTH SCREENING MARKET, BY REGION
GLOBAL HEALTH SCREENING MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
15.1 NORTH AMERICA
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
15.2 EUROPE
15.2.1 GERMANY
15.2.2 FRANCE
15.2.3 U.K.
15.2.4 ITALY
15.2.5 SPAIN
15.2.6 RUSSIA
15.2.7 TURKEY
15.2.8 BELGIUM
15.2.9 NETHERLANDS
15.2.10 SWITZERLAND
15.2.11 REST OF EUROPE
15.3 ASIA-PACIFIC
15.3.1 JAPAN
15.3.2 CHINA
15.3.3 SOUTH KOREA
15.3.4 INDIA
15.3.5 AUSTRALIA
15.3.6 SINGAPORE
15.3.7 THAILAND
15.3.8 MALAYSIA
15.3.9 INDONESIA
15.3.10 PHILIPPINES
15.3.11 REST OF ASIA-PACIFIC
15.4 SOUTH AMERICA
15.4.1 BRAZIL
15.4.2 ARGENTINA
15.4.3 REST OF SOUTH AMERICA
15.5 MIDDLE EAST AND AFRICA
15.5.1 SOUTH AFRICA
15.5.2 SAUDI ARABIA
15.5.3 UAE
15.5.4 EGYPT
15.5.5 ISRAEL
15.5.6 REST OF MIDDLE EAST AND AFRICA
15.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
16 GLOBAL HEALTH SCREENING MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
16.3 COMPANY SHARE ANALYSIS: EUROPE
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
16.5 MERGERS & ACQUISITIONS
16.6 NEW PRODUCT DEVELOPMENT & APPROVALS
16.7 EXPANSIONS
16.8 REGULATORY CHANGES
16.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
17 GLOBAL HEALTH SCREENING MARKET, SWOT AND DBMR ANALYSIS
18 GLOBAL HEALTH SCREENING MARKET, COMPANY PROFILE
18.1 QUEST DIAGNOSTICS
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 GRAIL
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 EXACT SCIENCES CORPORATION
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 EUROFINS SCIENTIFIC
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 UNILABS
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 LABPLUS
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 BIOREFERENCE HEALTH®, LLC
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 SONIC HEALTHCARE LIMITED
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 CERBA HEALTHCARE
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.1 INNOVA MEDICAL GROUP INC.
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 AMEDES GROUP
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 RADNET, INC
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 NATERA, INC
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 REPEATDX
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 NEOGENOMICS LABORATORIES
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 ARUP LABORATORIES
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 GENOVA DIAGNOSTICS (GDX)
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST RELATED REPORTS
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
